Acorda Therapeutics Inc. (ACOR) had a rough trading day for Friday October 11 as shares tumbled 9.74%, or a loss of $-0.26 per share, to close at $2.41. After opening the day at $2.67, shares of Acorda Therapeutics Inc. traded as high as $2.73 and as low as $2.40. Volume was 2.22 million shares over 7,899 trades, against an average daily volume of n/a shares and a total float of 48.11 million.
As a result of the decline, Acorda Therapeutics Inc. now has a market cap of $115.94 million. In the last year, shares of Acorda Therapeutics Inc. have traded between a range of $21.63 and $2.27, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders.Acorda uses scientific, clinical, and commercial expertise in neurology as strategic points of access in additional nervous system markets, including stroke, Parkinson’s disease, and epilepsy. The company does not operate separate lines of business with respect to any of its products or product candidates. All of its net product revenue is derived from the United States.
Acorda Therapeutics Inc. is based out of Ardsley, NY and has some 474 employees. Its CEO is Ron Cohen.
Acorda Therapeutics Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
